C71T
CANCELLED SECTION 71
23/01/2026
Voltar para busca
Dado oficial do USPTO
CURADIGM
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
17/02/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 42, 44
Data de depósito
01/08/2018
Data de registro
09/07/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/01/2026
Última transação
17/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
84
Localização do titular
FR
Examinador
BROWN, TRICIA
Unidade examinadora
N30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NANOBIOTIX
CURADIGM
Representantes
Dreyfus & associés
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Products for medical use especially for metabolic pathwaysenzyme substrates and enzyme inhibitors; products for medical use especially for the diagnosis and treatment of tumorsdiagnostic preparation for medical purposes for the diagnosis of tumors and therapeutic pharmaceutical preparations for medical purposes for the treatment of tumors and rare hepatic diseases; preparations for medical use especially for modifying the bioavailability of therapeutic agentslipidic and polymeric formulation for drug delivery in the nature of drug delivery agents in the form of nanoparticlesnanovesiclesparticlesvesiclesdissolvable filmscoatings for tablets and hydrogels that facilitate the delivery of pharmaceutical preparations; preparations for medical use especially for modifying liver functionspharmaceutical preparations for the treatment of liver diseases and disorders and pharmaceutical preparations to alter hepatic metabolization pathways; preparations for medical use for modifying the functions of the reticuloendothelial systempharmaceutical preparations for the treatment of reticuloendothelial system diseases and disorders and pharmaceutical preparations to alter reticuloendothelial system endocytosis pathways; preparations made with nanomaterials for the delivery of therapeutic agentsdrug delivery agents in the form of enterallyparenterally in the nature of intravenoustopically administered nanomaterials that facilitate the delivery of pharmaceutical preparations; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use for the treatment of cancercentral nervous system disorderscardiologicalimmunologicalgastrointestinalmetabolic and infection diseases; enzymes for medical use; enzyme preparations for medical use; chemical preparations for medical or pharmaceutical usefor the treatment of cancercentral nervous system disordercardiologicalimmunologicalgastrointestinalmetabolic and infection diseases; diagnostic products for medical usediagnostic preparations for medical purposes; drugs for medical usemedical preparations for the treatment of cancercentral nervous system disordercardiologicalimmunologicalgastrointestinalmetabolic and infectious diseases; medicines for human medicinemedical preparations for the treatment of cancercentral nervous system disordercardiologicalimmunologicalgastrointestinalmetabolic and infectious diseases; tonics medicinesmedical herbal preparations; antibiotics; antiseptics; chemico-pharmaceutical products for the treatment of the treatment of cancercentral nervous system disordercardiologicalimmunologicalgastrointestinalmetabolic and infection diseases; pharmaceutical productsdrug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; dietetic substances for medical usedietetic foods adapted for medical purposes; remedies for human medicinenatural remedy preparations for the treatment of gastrointestinal conditionshormonal and chemical imbalancessleep disorders
Classe 10
Surgical and medical apparatus and instruments especially for the diagnosis and treatment of tumors; Surgical and medical apparatus and instruments especially for monitoring and modifying metabolic functions; Apparatus for modifying the functions of the reticuloendothelial systemmedical apparatus and instruments for use in endovascular and cardiovascular procedures; Apparatus for modulating liver functionsmedical apparatus and instruments for use in measuringquantifying and assessing liver health and oxygenation and perfusion apparatus in the nature of perfusion pumps for liver transplantation; Apparatus for the delivery of therapeutic or diagnostic agentsmedical apparatus and units for dosagemeasuring and monitoringin the nature of drug delivery devices and systemsorgan oxygenation and perfusion apparatus in the nature of perfusion pumps; Apparatus for modulating hepatic blood floworgan perfusion apparatus in the nature of perfusion pumps; Testing apparatus for medical use in the nature of medical diagnostic apparatus for testing cancer callsDNAorgan oxygenation and blood sugar levels; Diagnostic apparatus for medical use for testing cancer callsDNAorgan oxygenation and blood sugar levels
Classe 42
Scientific and technological servicesresearch and design especially in the field of nanomedicinein the nature of nanotechnology applied to medicine; Biological research services; Bacteriological research services; Evaluationsestimates and research in scientific and technological fields provided by engineers and researchersconducting early evaluations in the field of new pharmaceuticals; Design and development of new products for third parties in the field of pharmaceutical preparations and diagnostic devices design; Technical research in the field of pharmaceutical project studies; Industrial analysis and research servicesbiomedical research services; Chemical analysis; Chemical research; Chemistry serviceschemistry consultation; Surveyingengineering work; Research and development of new products for others; Technical research in the field of pharmaceutical studies; Biological researchradiobiology researchbiologicalpharmacokineticpharmacodynamic and immunological evaluation and toxicological evaluation; Medical researchresearch in nanoscience and nanotechnologyespecially applied to medicine
Classe 44
Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
CHLD
CHANGE OF OWNER RECEIVED FROM IB
27/12/2024
CHLD
CHANGE OF OWNER RECEIVED FROM IB
27/02/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
15/11/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
29/10/2019
FIMP
FINAL DISPOSITION PROCESSED
29/10/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/10/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
09/07/2019
GPNX
NOTIFICATION PROCESSED BY IB
03/05/2019
PUBO
PUBLISHED FOR OPPOSITION
23/04/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/04/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
17/04/2019
NPUB
NOTICE OF PUBLICATION
03/04/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/03/2019
CNEA
EXAMINERS AMENDMENT MAILED
15/03/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
14/03/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/03/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/03/2019
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/03/2019
CNFR
FINAL REFUSAL MAILED
04/03/2019
CNFR
FINAL REFUSAL WRITTEN
01/03/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/02/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/02/2019
ALIE
ASSIGNED TO LIE
07/02/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/02/2019
RFNT
REFUSAL PROCESSED BY IB
21/12/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/12/2018
RFRR
REFUSAL PROCESSED BY MPU
04/12/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/11/2018
CNRT
NON-FINAL ACTION WRITTEN
18/11/2018
DOCK
ASSIGNED TO EXAMINER
18/11/2018
MAFR
APPLICATION FILING RECEIPT MAILED
13/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/11/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/11/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CURADIGM ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.